Reported Wednesday, Lexicon Published Data From RELIEF-DPN 1 Phase 2 Study Of LX9211 In Diabetes Care

6/20/24 5:19:54 AM ET

$LXRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LXRX alert in real time by email

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)
Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexicon's dose-ranging Phase 2b PROGRESS trial, currently enrolling patients

Get the next $LXRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LXRX

Date	Price Target	Rating	Analyst
6/17/2024	$10.00	Buy	H.C. Wainwright
4/30/2024	$5.00	Outperform	Leerink Partners
3/7/2023	$3.00	Hold	Jefferies
8/12/2022	$10.00	Overweight	Piper Sandler

More analyst ratings

$LXRX
Press Releases

Fastest customizable press release news feed in the world

Lexicon Appoints Ivan H. Cheung to Board of Directors
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis
11/20/24 4:05:47 PM ET
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago
THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association's (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois. One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the association of heart failure stage with cardiovascular disease and kidney events. Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with a corresponding increase in absolute benefi
11/14/24 8:00:00 AM ET
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP); Topline Data Expected in Q1 2025 Executed Repositioning of INPEFA® (sotagliflozin); Net Sales of $1.7 Million in Q3 2024 Conference Call and Webcast at 5:00pm ET THE WOODLANDS, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended September 30, 2024 and provided an update on key
11/12/24 4:05:00 PM ET
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care

$LXRX
Financials

Live finance-specific insights

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP); Topline Data Expected in Q1 2025 Executed Repositioning of INPEFA® (sotagliflozin); Net Sales of $1.7 Million in Q3 2024 Conference Call and Webcast at 5:00pm ET THE WOODLANDS, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended September 30, 2024 and provided an update on key
11/12/24 4:05:00 PM ET
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
THE WOODLANDS, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will release its third quarter 2024 financial results on Tuesday, November 12, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in InformationU.S. Dial-in Number: (888) 317-6003International Dial-in Number: (412) 317-6061Conference ID: 1004487 Replay InformationU.S. Dial-in Number: (877) 344-7529Replay International Dial-in Number: (412) 317-0088Conference ID: 7374787 The dial-in replay will be available for 7 days following the call
11/5/24 8:00:00 AM ET
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
INPEFA® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study of Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) Expect Topline Data in Q2 2025 from PROGRESS Phase 2b Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended June 30, 2024 and provided an update on key corporate milestones.
8/1/24 4:00:00 PM ET
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care

Reported Wednesday, Lexicon Published Data From RELIEF-DPN 1 Phase 2 Study Of LX9211 In Diabetes Care

Chat with this insight

Recent Analyst Ratings for $LXRX

$LXRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, Regulatory & QA Corrigan Brian

SEC Form 3 filed by new insider Corrigan Brian

New insider Siren, L.L.C. claimed ownership of 38,918,903 shares (SEC Form 3)

$LXRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

Coats Lonnel bought $10,100 worth of shares (10,000 units at $1.01), increasing direct ownership by 1% to 824,359 units (SEC Form 4)

Debbane Raymond bought $1,103,957 worth of shares (1,000,000 units at $1.10), increasing direct ownership by 293% to 1,340,847 units (SEC Form 4)

$LXRX Leadership Updates

Live Leadership Updates

Lexicon Appoints Ivan H. Cheung to Board of Directors

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

$LXRX Press Releases

Fastest customizable press release news feed in the world

Lexicon Appoints Ivan H. Cheung to Board of Directors

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

$LXRX Financials

Live finance-specific insights

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

$LXRX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

$LXRX SEC Filings

Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$LXRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

$LXRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target

Leerink Partners initiated coverage on Lexicon Pharma with a new price target

Jefferies initiated coverage on Lexicon Pharma with a new price target

$LXRX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target

Lexicon Pharmaceuticals Receives Dec. 20, 2024 PDUFA Goal Date For Sotagliflozin Type 1 Diabetes NDA Resubmission

Recent Analyst Ratings for
$LXRX

$LXRX
Insider Trading

$LXRX
Insider Purchases

$LXRX
Leadership Updates

$LXRX
Press Releases

$LXRX
Financials

$LXRX
FDA approvals

$LXRX
SEC Filings

$LXRX
Large Ownership Changes

$LXRX
Analyst Ratings

$LXRX
Market Insights